PLK1 and acute myeloid leukemia: This possibility can be readily explored as volasertib, a PLK1 inhibitor, has been granted Orpha Drug Designation status in treating AML (acute myeloid leukemia) in 2014 and rhabdomyosarcoma in 2020 (https://oncoheroes.com/press-releases-content/2020/10/14/volasertib-a-potential-new-treatment-for-rhabdomyosarcoma-receives-orphan-drug-designation-from-the-us-fda, accessed on 31 May 2021) by FDA.